NEUROLOGY 1996;46:1633-1638
© 1996 American Academy of Neurology
Interferon-beta sub 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis
S. A. Brod, MD,
G. D. Marshall, Jr., MD, PhD,
E. M. Henninger, BA,
S. Sriram, MD,
M. Khan, BS and
J. S. Wolinsky, MD
From the Departments of Neurology (Drs. Brod and Wolinsky and Mr. Khan) and Internal Medicine (Dr. Marshall and Mrs. Henninger), University of Texas-Houston, Health Science Center, Houston, TX; and the Department of Neurology (Dr. Sriram), Vanderbilt Stallworth Research Hospital, Nashville, TN.
Supported in part by a grant from the Clayton Foundation.
Received March 22, 1995. Accepted in final form September 29, 1995.
Address correspondence and reprint requests to Dr. Staley A. Brod, University of Texas Health Science Center at Houston, Department of Neurology, 7.044, P.O. Box 20708, Houston, TX 77225.
MS is presumed to be a T-cell-mediated chronic inflammatory disease of the CNS. We examined proliferation and cytokine secretion of mononuclear cells after stimulation with OKT3 [anti-CD3] monoclonal antibody (MAb) or concanavalin A (Con A) in subjects with stable relapsing-remitting MS (RR MS) before and after initiating interferon (IFN)-beta1b treatment. There was no significant difference in pretreatment to on-treatment anti-CD3 mAb or Con A-induced proliferation in RR MS patients. There was significantly increased Con A-induced secretion of tumor necrosis factor (TNF)-alpha, IFN-gamma, interleukin (IL)-2, IL-6, and IL-10 and decreased IL-4 secretion in on-treatment compared with pretreatment peripheral blood mononuclear cell samples. However, on-treatment CD3-mediated secretion of TNF-alpha was significantly decreased, and IL-6 secretion was significantly increased compared with pretreatment values. IFN-gamma was also decreased in on-treatment cultures stimulated with anti-CD3 MAb, but these values did not reach statistical significance. Systemic side effects from IFN-beta1b were associated with increased IL-6 secretion. There were no significant changes in CD3-mediated IL-4, IL-10, transforming growth factor (TGF)-beta, or IL-2 secretion or Con A-induced TGF-beta secretion. IFN-beta1b (Betaseron) decreases CD3-mediated TNF-alpha secretion but increases another inflammatory cytokine, IL-6, that could potentially counteract its beneficial immunomodulatory effects.
NEUROLOGY 1996;46: 1633-1638
This article has been cited by other articles:
|
|
|
|
 
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt
Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro
Multiple Sclerosis,
July 1, 2008;
14(6):
843 - 852.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Ghosh, R Chaudhary, M Carpani, and R Playford
Interfering with interferons in inflammatory bowel disease.
Gut,
August 1, 2006;
55(8):
1071 - 1073.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L M Metz, S B Patten, C J Archibald, J I Bakker, C J Harris, D G Patry, R B Bell, M Yeung, W F Murphy, C A Stoian, et al.
The effect of immunomodulatory treatment on multiple sclerosis fatigue
J. Neurol. Neurosurg. Psychiatry,
July 1, 2004;
75(7):
1045 - 1047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Nikolaus, P Rutgeerts, R Fedorak, A H Steinhart, G E Wild, D Theuer, J Mohrle, and S Schreiber
Interferon {beta}-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study
Gut,
September 1, 2003;
52(9):
1286 - 1290.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. A. Brod
Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity
Exp Biol Med,
December 1, 2002;
227(11):
981 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Brod, J. W. Lindsey, F. S. Vriesendorp, C. Ahn, E. Henninger, P. A. Narayana, and J. S. Wolinsky
Ingested IFN-{alpha}: Results of a pilot study in relapsing-remitting MS
Neurology,
September 11, 2001;
57(5):
845 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chabot and V. W. Yong
Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: Relevance to MS
Neurology,
November 28, 2000;
55(10):
1497 - 1505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kumpfel, F. T. Bergh, T. Pollmacher, F. Holsboer, and C. Trenkwalder
Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS
Neurology,
October 24, 2000;
55(8):
1231 - 1233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kracke, P. von Wussow, A. N. Al-Masri, G. Dalley, A. Windhagen, and F. Heidenreich
Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
Neurology,
January 11, 2000;
54(1):
193 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. U. Walther and R. Hohlfeld
Multiple sclerosis: Side effects of interferon beta therapy and their management
Neurology,
November 1, 1999;
53(8):
1622 - 1622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gayo, L. Mozo, A. Suarez, A. Tunon, C. Lahoz, and C. Gutierrez
Interferon beta-1b treatment modulates TNF{alpha} and IFN{gamma} spontaneous gene expression in MS
Neurology,
June 1, 1999;
52(9):
1764 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bakhiet, V. Ozenci, C. Withagen, M. Mustafa, S. Fredrikson, and H. Link
A New Cell Enzyme-Linked Immunosorbent Assay Demonstrates Gamma Interferon Suppression by Beta Interferon in Multiple Sclerosis
Clin. Vaccine Immunol.,
May 1, 1999;
6(3):
415 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F Smith and C. L Darlington
Recent developments in drug therapy for multiple sclerosis
Multiple Sclerosis,
April 1, 1999;
5(2):
110 - 120.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Bongioanni, F. Lombardo, G. Moscato, S. Mosti, and G. Meucci
T-Cell Interferon Gamma Receptor Binding in Interferon Beta-1b-Treated Patients With Multiple Sclerosis
Arch Neurol,
February 1, 1999;
56(2):
217 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bongioanni, S. Mosti, G. Moscato, F. Lombardo, C. Manildo, and G. Meucci
Decreases in T-Cell Tumor Necrosis Factor {alpha} Binding With Interferon Beta Treatment in Patients With Multiple Sclerosis
Arch Neurol,
January 1, 1999;
56(1):
71 - 78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M Ferrarini, S Sivieri, M Buttarello, A Facchinetti, P Perini, and P Gallo
Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-{beta}1b-treated multiple sclerosis patients
Multiple Sclerosis,
June 1, 1998;
4(3):
174 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A J Coles, M G Wing, and D A. Compston
Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy
Multiple Sclerosis,
June 1, 1998;
4(3):
232 - 238.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A Brod, R. H Kerman, L. D Nelson, G. D Marshall JR, E. M Henninger, M. Khan, R. Jin, and J. S Wolinsky
Ingested IFN-{alpha} has biological effects in humans with relapsing-remitting multiple sclerosis
Multiple Sclerosis,
February 1, 1997;
3(1):
1 - 7.
[Abstract]
[PDF]
|
|
|
|
